Vacunas frente al virus del papiloma humano: actualización

Vaccination against human papillomavirus (HPV) is a recently developed preventive tool with a major impact on primary cancer prevention. Because of the pace at which new data appear, a constant effort is required to keep up to date. The present review discusses and provides an update on the immunogenicity, efficacy, safety and efficiency of the two currently available vaccines, Cervarix®, a bivalent vaccine for the prevention of HPV 16- and 18-associated cervical cancer, and Gardasil®, a tetravalent vaccine against HPV types 6, 11, 16, and 18.